Hyperkalemia in heart failure: a barrier to optimal drug treatment
10.3760/cma.j.issn.0254-9026.2025.01.014
- VernacularTitle:心力衰竭中的高钾血症：阻碍最优药物治疗的暗礁
- Author:
Yuhao WAN
1
;
Hua WANG
1
;
Jiefu YANG
1
Author Information
1. 北京医院心内科 国家老年医学中心 中国医学科学院老年医学研究院，北京 100730
- Publication Type:Journal Article
- Keywords:
Heart failure;
Hyperkalemia;
Renin-angiotensin-aldosterone system inhibitors
- From:
Chinese Journal of Geriatrics
2025;44(1):81-86
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure(HF)is a clinical syndrome that poses a significant threat to patient lives.Renin-angiotensin-aldosterone system inhibitors(RAASi)represent a cornerstone therapy for heart failure with reduced ejection fraction, enhancing patient prognosis.Hyperkalemia is a prevalent complication of HF and a common adverse effect associated with the use of RAASi, often resulting in the withdrawal or dose reduction of these medications in certain heart failure patients during clinical practice.A debate exists regarding whether hyperkalemia itself, or the insufficient dosing of RAASi due to hyperkalemia, contributes to poor outcomes in HF patients.This article reviews recent domestic and international research on HF associated with hyperkalemia and discusses the effects of hyperkalemia and RAASi treatment patterns on the clinical outcomes of HF patients, while exploring strategies for managing hyperkalemia in this population.
